NCT05464719

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.

Detailed description

Primary Objective: -To evaluate the efficacy of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy. Secondary Objectives: -To evaluate safety and tolerability of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy. Exploratory Objective: -To determine the pharmacodynamic effects and investigate biomarkers of response and resistance of this novel consolidation therapy.

Conditions

• Large B-cell Lymphoma
• Lymphoma

Interventions

Type	Name	Description
DRUG	Loncastuximab Tesirine	Given by IV

Timeline

• Start date: 2022-09-23
• Primary completion: 2030-01-30
• Completion: 2030-01-30
• First posted: 2022-07-19
• Last updated: 2026-01-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study